Skip to main content
Clinical Trials/NCT01776515
NCT01776515
Completed
Phase 1

A Randomized, Double-blind, Active-controlled, Parallel, Multicenter Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Low Back Pain Patients

Overview

Phase
Phase 1
Intervention
Tramadol hydrochloride/Acetaminophen Tab.
Conditions
Low Back Pain
Sponsor
Daewon Pharmaceutical Co., Ltd.
Primary Endpoint
Changes in '100 mm pain VAS' value from baseline
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to evaluate effectness of Tramadol Hydrochloride/Acetaminophen SR Tab. and Tramadol Hydrochloride/Acetaminophen Tab. in patients with low back pain.

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
June 2012
Last Updated
13 years ago
Study Type
Interventional
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult males/Females aged over 20 years
  • Patient with low back pain who needs analgesic administration
  • Patient with low back pain Who correspond with Class 1, 2 in Quebec Task Force Classification
  • Pain VAS Value over 40 mm
  • Subjects who voluntarily or legal guardian agreed with written consent

Exclusion Criteria

  • Patients with severe GI tract disorder, liver disease, renal disease, heart disease, hypertension
  • Patients with obvious secondary cause(metastatic cancer, fracture, infectious disease)
  • Patients who had taken back surgery within 24 weeks from the screening point
  • Patients who had taken opioid drug, psychotropic drug within 4 weeks from the screening point
  • Patients who had taken steroid drug(oral, injection) within 4 weeks from the screening point

Arms & Interventions

Tramadol hydrochloride/Acetaminophen Tab.

Intervention: Tramadol hydrochloride/Acetaminophen Tab.

Tramadol hydrochloride/Acetaminophen SR Tab.

Intervention: Tramadol hydrochloride/Acetaminophen SR Tab.

Outcomes

Primary Outcomes

Changes in '100 mm pain VAS' value from baseline

Time Frame: 0, 1, 7, 14, 28 day

Similar Trials